journal article·2026-07Open access

Efficient prime editing in vivo and in vitro using lipid nanoparticles

Allen Y. Jiang, Ana Cristian, Dominique L. Brooks, Emily R. Feierman, Paul Z. Chen, Madelynn N. Whittaker, Sarah E. Pierce, Holt A. Sakai, Hongyu Chen, Dangliang Liu, Peyton B. Randolph, Angus H. Li, Alvin Hsu, Serena O. Omo-Lamai, Y. Allen Tao, Benista Owusu-Amo, Xiao Wang, Xiao Wang, Kiran Musunuru, David R. Liu

Nature Nanotechnology· Volume 21· Issue 7

Abstract

Abstract Prime editing is a versatile clinical genome editing method that enables precise substitutions, small insertions and deletions at specified locations in the genomes of living systems including human cells. Although non-viral lipid nanoparticle (LNP) delivery of RNA in vivo has become a preferred method for gene editing in animals and patients, its application to complex, three-component prime editing systems has yielded low editing efficiencies. Here we developed a systematic prime editing LNP (PE-LNP) optimization platform that addresses key bottlenecks in cargo design that limit editing efficiency. This generalizable workflow yielded PE-LNPs that can achieve 49% average in vivo prime editing in the bulk mouse liver with a single dose of 2 mg kg −1 . We applied our workflow to the correction of PAH R408W, a cause of phenylketonuria, in a mouse model and achieved prime editing efficiencies and serum phenylalanine levels anticipated to be curative. We also show that PE-LNPs minimize off-target editing compared with DNA delivery methods, induce only transient elevation of liver enzymes and can be dosed repeatedly to improve editing efficiencies. These PE-LNP systems provide an attractive alternative to viral delivery by offering transient expression that minimizes off-target editing, no observed long-term toxicity and high levels of non-viral in vivo liver prime editing.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: CRISPR and Genetic Engineering · RNA regulation and disease · Biotin and Related Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (69)

Show source-provided references
1. Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019).10.1038/s41586-019-1711-4 ↗
2. Heath, J. M. et al. Prime editing efficiently and precisely corrects causative mutation in chronic granulomatous disease, restoring myeloid function: toward development of a prime edited autologous hematopoietic stem cell therapy. Blood 142, 7129–7129 (2023).10.1182/blood-2023-186365 ↗
3. Everette, K. A. et al. Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice. Nat. Biomed. Eng. 7, 616–628 (2023).10.1038/s41551-023-01026-0 ↗
4. Li, C. et al. In vivo HSC prime editing rescues sickle cell disease in a mouse model. Blood 141, 2085–2099 (2023).
5. Sousa, A. A. et al. In vivo prime editing rescues alternating hemiplegia of childhood in mice. Cell 188, 4275–4294 (2025).10.1016/j.cell.2025.06.038 ↗
6. Qin, H. et al. Vision rescue via unconstrained in vivo prime editing in degenerating neural retinas. J. Exp. Med. 220, e20220776 (2023).10.1084/jem.20220776 ↗
7. Fu, Y. et al. In vivo prime editing rescues photoreceptor degeneration in nonsense mutant retinitis pigmentosa. Nat. Commun. 16, 2394 (2025).10.1038/s41467-025-57628-6 ↗
8. Jang, H. et al. Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases. Nat. Biomed. Eng. 6, 181–194 (2021).10.1038/s41551-021-00788-9 ↗
9. An, M. et al. Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nat. Biotechnol. 42, 1526–1537 (2024).10.1038/s41587-023-02078-y ↗
10. Brooks, D. L. et al. Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need. Am. J. Hum. Genet. 110, 2003–2014 (2023).10.1016/j.ajhg.2023.10.005 ↗
11. Böck, D. et al. In vivo prime editing of a metabolic liver disease in mice. Sci. Transl. Med. 14, eabl9238 (2022).10.1126/scitranslmed.abl9238 ↗
12. Rothgangl, T. et al. Treatment of a metabolic liver disease in mice with a transient prime editing approach. Nat. Biomed. Eng. 9, 1705–1718 (2025).10.1038/s41551-025-01399-4 ↗
13. Liu, P. et al. Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nat. Commun. 12, 2121 (2021).10.1038/s41467-021-22295-w ↗
14. Gillmore, J. D. et al. CRISPR–Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493–502 (2021).10.1056/NEJMoa2107454 ↗
15. Musunuru, K. et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N. Engl. J. Med. 392, 2235–2243 (2025).10.1056/NEJMoa2504747 ↗
16. Beam Therapeutics. Beam Therapeutics presents additional data for BEAM-302 in alpha-1 antitrypsin deficiency (AATD). In 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-presents-additional-data-beam-302-alpha-1 (2025).
17. Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429–434 (2021).10.1038/s41586-021-03534-y ↗
18. Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).10.1038/s41578-021-00358-0 ↗
19. Paunovska, K., Loughrey, D. & Dahlman, J. E. Drug delivery systems for RNA therapeutics. Nat. Rev. Genet. 23, 265–280 (2022).10.1038/s41576-021-00439-4 ↗
20. Hosseini-Kharat, M., Bremmell, K. E. & Prestidge, C. A. Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism. Mol. Ther. Methods Clin. Dev. 33, 101436 (2025).10.1016/j.omtm.2025.101436 ↗
21. Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357–1364 (2010).10.1038/mt.2010.85 ↗
22. Chen, Z. et al. In vivo prime editing by lipid nanoparticle co-delivery of chemically modified pegRNA and prime editor mRNA. GEN Biotechnol. 2, 490–502 (2023).10.1089/genbio.2023.0045 ↗
23. Liu, P. et al. Increasing intracellular dNTP levels improves prime editing efficiency. Nat. Biotechnol. 43, 539–544 (2024).10.1038/s41587-024-02405-x ↗
24. Nelson, J. W. et al. Engineered pegRNAs improve prime editing efficiency. Nat. Biotechnol. 40, 402–410 (2021).10.1038/s41587-021-01039-7 ↗
25. Yan, J. et al. Improving prime editing with an endogenous small RNA-binding protein. Nature 628, 639–647 (2024).10.1038/s41586-024-07259-6 ↗
26. Doman, J. L. et al. Phage-assisted evolution and protein engineering yield compact, efficient prime editors. Cell 186, 3983–4002 (2023).10.1016/j.cell.2023.07.039 ↗
27. Sakai, H. A. et al. Directed evolution of small RNA-stabilizing motifs that improve prime editing. Nat. Biotechnol. https://doi.org/10.1038/s41587-026-03123-2 (2026).10.1038/s41587-026-03123-2 ↗
28. Fenton, O. S. et al. Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery. Adv. Mater. 28, 2939–2943 (2016).10.1002/adma.201505822 ↗
29. Herrera-Barrera, M. et al. Lipid nanoparticle-enabled intracellular delivery of prime editors. AAPS J. 25, 65 (2023).10.1208/s12248-023-00833-2 ↗
30. Davis, K. M., Pattanayak, V., Thompson, D. B., Zuris, J. A. & Liu, D. R. Small molecule–triggered Cas9 protein with improved genome-editing specificity. Nat. Chem. Biol. 11, 316–318 (2015).10.1038/nchembio.1793 ↗
31. Zuris, J. A. et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33, 73–80 (2014).10.1038/nbt.3081 ↗
32. Rees, H. A. et al. Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat. Commun. 8, 15790 (2017).10.1038/ncomms15790 ↗
33. Banskota, S. et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185, 250–265 (2022).10.1016/j.cell.2021.12.021 ↗
34. Li, S. et al. Payload distribution and capacity of mRNA lipid nanoparticles. Nat. Commun. 13, 5561 (2022).10.1038/s41467-022-33157-4 ↗
35. Shuto, Y. et al. Structural basis for pegRNA-guided reverse transcription by a prime editor. Nature 631, 224–231 (2024).10.1038/s41586-024-07497-8 ↗
36. Zhang, W. et al. Enhancing CRISPR prime editing by reducing misfolded pegRNA interactions. Elife 12, RP90948 (2024).10.7554/eLife.90948.2 ↗
37. Baiersdörfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26–35 (2019).10.1016/j.omtn.2019.02.018 ↗
38. Chatterjee, S., Kon, E., Sharma, P. & Peer, D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc. Natl Acad. Sci. USA 121, e2307800120 (2024).10.1073/pnas.2307800120 ↗
39. Hassett, K. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1–11 (2019).10.1016/j.omtn.2019.01.013 ↗
40. Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in Vivo. Angew. Chem. Int. Ed. 51, 8529–8533 (2012).10.1002/anie.201203263 ↗
41. Cheng, M. H. Y. et al. Induction of bleb structures in lipid nanoparticle formulations of mRNA leads to improved transfection potency. Adv. Mater. 35, 2303370 (2023).10.1002/adma.202303370 ↗
42. Finn, J. D. et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227–2235 (2018).10.1016/j.celrep.2018.02.014 ↗
43. Li, L. et al. Glucocorticoid pre-administration improves LNP-mRNA mediated protein replacement and genome editing therapies. Int. J. Pharm. 672, 125282 (2025).10.1016/j.ijpharm.2025.125282 ↗
44. Andries, O. et al. N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J. Control. Release 217, 337–344 (2015).10.1016/j.jconrel.2015.08.051 ↗
45. Brooks, D. L. et al. A base editing strategy using mRNA-LNPs for in vivo correction of the most frequent phenylketonuria variant. Hum. Genet. Genom. Adv. 5, 100253 (2024).10.1016/j.xhgg.2023.100253 ↗
46. Lee, R. G. et al. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation 147, 242–253 (2023).10.1161/CIRCULATIONAHA.122.062132 ↗
47. Hillert, A. et al. The genetic landscape and epidemiology of phenylketonuria. Am. J. Hum. Genet. 107, 234–250 (2020).10.1016/j.ajhg.2020.06.006 ↗
48. van Spronsen, F. J. et al. Phenylketonuria. Nat. Rev. Dis. Primers 7, 36 (2021).10.1038/s41572-021-00267-0 ↗
49. Vockley, J. et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet. Med. 16, 188–200 (2014).10.1038/gim.2013.157 ↗
50. Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J.-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24, 1012–1019 (2014).10.1101/gr.171322.113 ↗
51. Ramakrishna, S. et al. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 24, 1020–1027 (2014).10.1101/gr.171264.113 ↗
52. Cameron, P. et al. Mapping the genomic landscape of CRISPR–Cas9 cleavage. Nat. Methods 14, 600–606 (2017).10.1038/nmeth.4284 ↗
53. Lattanzi, A. et al. Optimization of CRISPR/Cas9 delivery to human hematopoietic stem and progenitor cells for therapeutic genomic rearrangements. Mol. Ther. 27, 137–150 (2019).10.1016/j.ymthe.2018.10.008 ↗
54. Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR–Cas nucleases. Nat. Biotechnol. 33, 187–197 (2014).10.1038/nbt.3117 ↗
55. Davis, J. R. et al. Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nat. Biotechnol. 42, 253–264 (2023).10.1038/s41587-023-01758-z ↗
56. Bish, L. T. et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene Ther. 19, 1359–1368 (2008).10.1089/hum.2008.123 ↗
57. Habib, O., Habib, G., Hwang, G.-H. & Bae, S. Comprehensive analysis of prime editing outcomes in human embryonic stem cells. Nucleic Acids Res. 50, 1187–1197 (2022).10.1093/nar/gkab1295 ↗
58. Gao, R. et al. Genomic and Transcriptomic analyses of prime editing guide RNA–independent off-target effects by prime editors. CRISPR J. 5, 276–293 (2022).10.1089/crispr.2021.0080 ↗
59. Liang, S.-Q. et al. Genome-wide profiling of prime editor off-target sites in vitro and in vivo using PE-tag. Nat. Methods 20, 898–907 (2023).10.1038/s41592-023-01859-2 ↗
60. Fiumara, M. et al. Author Correction: Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nat. Biotechnol. 42, 986–986 (2024).10.1038/s41587-024-02142-1 ↗
61. Kim, D. Y., Moon, S. B., Ko, J.-H., Kim, Y.-S. & Kim, D. Unbiased investigation of specificities of prime editing systems in human cells. Nucleic Acids Res. 48, 10576–10589 (2020).10.1093/nar/gkaa764 ↗
62. Zhang, H. et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621, 396–403 (2023).10.1038/s41586-023-06127-z ↗
63. Chen, H. et al. Chemical and topological design of multicapped mRNA and capped circular RNA to augment translation. Nat. Biotechnol. 43, 1128–1143 (2024).10.1038/s41587-024-02393-y ↗
64. Chen, H. et al. Branched chemically modified poly(A) tails enhance the translation capacity of mRNA. Nat. Biotechnol. 43, 194–203 (2024).10.1038/s41587-024-02174-7 ↗
65. Lei, X. et al. Rapid generation of long, chemically modified pegRNAs for prime editing. Nat. Biotechnol. 43, 1156–1167 (2024).10.1038/s41587-024-02394-x ↗
66. Ryan, D. E. et al. Phosphonoacetate modifications enhance the stability and editing yields of guide RNAs for Cas9 editors. Biochemistry 62, 3512–3520 (2022).10.1021/acs.biochem.1c00768 ↗
67. Yin, H. et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat. Biotechnol. 35, 1179–1187 (2017).10.1038/nbt.4005 ↗
68. Chen, D. et al. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J. Am. Chem. Soc. 134, 6948–6951 (2012).10.1021/ja301621z ↗
69. Ma, Y., VanKeulen-Miller, R. & Fenton, O. S. mRNA lipid nanoparticle formulation, characterization and evaluation. Nat. Protoc. 20, 2618–2651 (2025).10.1038/s41596-024-01134-4 ↗